Evidence map›Paper›PMID 37183588›Full record

Observational studyJournal of diabetes investigation2023

Impact of COVID-19 pandemic on behavioral changes and glycemic control and a survey of telemedicine in patients with diabetes: A multicenter retrospective observational study.

Ryotaro Bouchi, Takehiro Sugiyama, Atsushi Goto, Mitsuru Ohsugi, Narihito Yoshioka, Hideki Katagiri, Tomoya Mita, Yushi Hirota, Hiroshi Ikegami, Munehide Matsuhisa and 11 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of diabetes investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ryotaro BouchiDepartment of Diabetes, Endocrinology and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7664-4342
Takehiro SugiyamaDiabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5391-682X
Atsushi GotoDepartment of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0003-0669-654X
Mitsuru OhsugiDepartment of Diabetes, Endocrinology and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.
Narihito YoshiokaNTT Medical Center Sapporo, Sapporo, Japan.
Hideki KatagiriDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0003-1093-3704
Tomoya MitaDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4401-2965
Yushi HirotaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0002-3035-4155
Hiroshi IkegamiDepartment of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-8808-4605
Munehide MatsuhisaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0003-4624-939X
Eiichi ArakiDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-4064-7525
Hiroki YokoyamaJiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan.ORCID https://orcid.org/0000-0003-1602-4050
Masae MinamiMinami Diabetes Clinical Research Center, Fukuoka, Japan.
Katsuya YamazakiKawai Clinic, Tsukuba, Japan.
Hideaki JinnouchiJinnouchi Hospital Diabetes Care Center, Kumamoto, Japan.
Hiroki IkedaIkeda Hospital, Amagasaki, Japan.
Hitomi FujiiTama-Center Mirai Clinic, Tokyo, Japan.
Miyuki NogawaClinic Mirai Kunitachi, Tokyo, Japan.
Masahiro KaneshigeClinic Mirai Tachikawa, Tokyo, Japan.
Kengo MiyoCenter for Medical Informatics Intelligence, National Center for Global Health and Medicine, Tokyo, Japan.
Kohjiro UekiDepartment of Diabetes, Endocrinology and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

Health and Labour Sciences Research Grant 21CA2021
6 · The paper itself

Abstract

AIMS/

introductionTo investigate whether the COVID-19 pandemic affected behavioral changes and glycemic control in patients with diabetes and to conduct a survey of telemedicine during the pandemic. MATERIALS AND

methodsIn this retrospective study, a total of 2,348 patients were included from 15 medical facilities. Patients were surveyed about their lifestyle changes and attitudes toward telemedicine. Hemoglobin A1c (HbA1c) levels were compared among before (from June 1 to August 31, 2019) and in the first (from June 1 to August 31, 2020) and in the second (from June 1 to August 31, 2021) year of the pandemic. A survey of physician attitudes toward telemedicine was also conducted.

resultsThe HbA1c levels were comparable between 2019 (7.27 ± 0.97%), 2020 (7.28 ± 0.92%), and 2021 (7.25 ± 0.94%) without statistical difference between each of those 3 years. Prescriptions for diabetes medications increased during the period. The frequency of eating out was drastically reduced (51.7% in 2019; 30.1% in 2020), and physical activity decreased during the pandemic (48.1% in 2019; 41.4% in 2020; 43.3% in 2021). Both patients and physicians cited increased convenience and reduced risk of infection as their expectations for telemedicine, while the lack of physician-patient interaction and the impossibility of consultation and examination were cited as sources of concern.

conclusionsOur data suggest that glycemic control did not deteriorate during the COVID-19 pandemic with appropriate intensification of diabetes treatment in patients with diabetes who continued to attend specialized diabetes care facilities, and that patients and physicians shared the same expectations and concerns about telemedicine.

Indexed as

COVID-19Diabetes MellitusTelemedicineGlycated HemoglobinGlycemic ControlHumansPandemicsRetrospective StudiesGlycated HemoglobinCOVID-19glycemic controllifestyle changes

Identifiers

PMID37183588
PMCPMC10360386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.